ADHD Suicidal Thinking Health Advisory Limited To Lilly’s Strattera
Executive Summary
FDA does not intend to release a general public health advisory for attention deficit/hyperactivity disorder medications despite issuing one for Lilly's Strattera (atomoxetine) Sept. 29
You may also be interested in...
Sparlon Is In Strattera Stratum With Regard To Efficacy, Committee Says
Efficacy of Cephalon's attention deficit/hyperactivity disorder drug Sparlon should be considered to be in the range of Lilly's Strattera, FDA's Psychopharmacologic Drugs Advisory Committee said March 23
Sparlon Is In Strattera Stratum With Regard To Efficacy, Committee Says
Efficacy of Cephalon's attention deficit/hyperactivity disorder drug Sparlon should be considered to be in the range of Lilly's Strattera, FDA's Psychopharmacologic Drugs Advisory Committee said March 23
Suicidality Risk With ADHD Drugs Should Be Treated As Class Effect – Cmte.
The risk of suicidality in children receiving drugs to treat attention deficit/hyperactivity disorder should be viewed as a class effect, FDA's Pediatric Advisory Committee recommended March 22